In the Original Investigation titled “Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer,”1 published online September 17, 2019, and in the November 2019 print issue, a hazard ratio (HR) and the 95% CIs regarding the difference in overall survival (OS) for patients with adenocarcinoma vs those with squamous cell carcinoma (SCC) in the last sentence of the Results were incorrect owing to misoperation in data entry. The last sentence should read “The difference in OS was more pronounced for patients with adenocarcinoma (HR, 0.70; 95% CI, 0.47-0.94; P = .02) than those with SCC (HR, 1.43; 95% CI, 0.79-2.58; P = .23).” This article has been corrected online.
1.Chen D, Menon H, Verma V,
et al. Results of a phase 1/2 trial of chemoradiotherapy with simultaneous integrated boost of radiotherapy dose in unresectable locally advanced esophageal cancer.
JAMA Oncol. 2019;5(11):1597-1604. doi:
10.1001/jamaoncol.2019.2809PubMedGoogle ScholarCrossref